先進(jìn)的藥物發(fā)現(xiàn)技術(shù)正在使?jié)撛诘暮蜻x藥物數(shù)量急劇增加。然而，這些化合物的優(yōu)化越來越依賴于吸收、分布、代謝和排泄（ADME）以及毒理學(xué)（TOX）問題，這是藥物發(fā)現(xiàn)過程中的一個(gè)主要瓶頸。在藥物研究中，至少50%的藥物失敗被認(rèn)為是由于ADME的毒性考慮。因此，在臨床試驗(yàn)前解決藥物候選藥物的ADME毒性問題的能力，對于提高藥物開發(fā)過程的效率和成本效益至關(guān)重要。此外，繼續(xù)研究現(xiàn)有化合物周圍的代謝、藥代動(dòng)力學(xué)和毒理學(xué)問題，對于優(yōu)化藥物方案和治療策略具有重要意義。通過系統(tǒng)的審查和評估，藥物代謝和毒理學(xué)專家意見提供了一個(gè)論壇，用于評論和分析ADME毒理學(xué)領(lǐng)域當(dāng)前和新出現(xiàn)的研究方法，以及與特定藥物或藥物類別相關(guān)的代謝、藥代動(dòng)力學(xué)和毒理學(xué)問題。該期刊包含以下文章類型：綜述----涵蓋藥物代謝和毒理學(xué)的各個(gè)方面，包括體外化驗(yàn)、體外、體內(nèi)和體內(nèi)的毒理學(xué)篩選，以及藥物動(dòng)力學(xué)研究；藥物評價(jià)----評估代謝，與某一特定藥物有關(guān)的藥代動(dòng)力學(xué)和毒理學(xué)問題；技術(shù)簡介----提供對個(gè)別技術(shù)的分析，使讀者全面了解所審查的具體技術(shù)；觀點(diǎn)----突出該領(lǐng)域內(nèi)的爭議和辯論領(lǐng)域；會(huì)議要點(diǎn)----報(bào)道最近的相關(guān)會(huì)議；社論----涉及與藥物代謝和毒理學(xué)有關(guān)的重要問題。聽眾包括保健和制藥行業(yè)的科學(xué)家和管理人員、學(xué)術(shù)制藥科學(xué)家和相關(guān)專業(yè)人員。

Advanced drug discovery technologies are yielding a dramatic increase in the number of potential drug candidates. However, optimisation of these compounds is becoming increasingly reliant on absorption, distribution, metabolism and excretion (ADME), and toxicological (Tox) issues, a major bottleneck in the drug discovery process. At least 50% of all drug failures in pharmaceutical research are believed to be due to ADME-Tox considerations. Therefore, the ability to solve the ADME-Tox issues of a drug candidate before clinical testing has become of utmost importance in rendering the drug development process more efficient and cost-effective. Furthermore, the continued study of metabolic, pharmacokinetic and toxicological issues surrounding existing compounds is of great importance in the optimisation of drug regimens and therapeutic strategies. Through systematic review and evaluation, Expert Opinion on Drug Metabolism & Toxicology provides a forum for the commentary and analysis of current and emerging research approaches in the ADME-Tox arena, as well as metabolic, pharmacokinetic and toxicological issues relating to specific drugs or drug classes. The journal contains the following article types: Reviews - cover every aspect of drug metabolism and toxicology including in vitro assays, toxicology screens, in vitro, in vivo and in silico ADME models, and pharmacokinetic studies; Drug Evaluations - assess metabolic, pharmacokinetic and toxicological issues related to a specific drug; Technology Profiles - provide analysis of individual technologies, offering readers a comprehensive overview of the specific technology under review; Perspectives - highlight areas of controversy and debate within the field; Meeting Highlights - provide coverage of recent related conferences; Editorials - cover important issues pertaining to drug metabolism and toxicology. The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and related professionals.